Dr. Francesco Forconi on B-cell Receptor Structure and Function in CLL

Francesco Forconi, MD
Published: Wednesday, Jul 06, 2016

 
Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).
 
CLL is a disease with a very variable outcome, says Forconi.  It was recently published that the ability of CLL to progress depends on the BCR immunoglobulin (IgM) levels and the BCR signaling levels. Those cells that have a stronger capacity through IgM will progress more rapidly than those that have low IgM signaling capacity or lower IgM levels.  
 
By targeting this molecule it may be possible to improve outcomes, says Forconi. A better understanding of how the BCR functions in CLL will make it easier to design a therapeutic regimen to fight the disease, he says.
 
Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).
 
CLL is a disease with a very variable outcome, says Forconi.  It was recently published that the ability of CLL to progress depends on the BCR immunoglobulin (IgM) levels and the BCR signaling levels. Those cells that have a stronger capacity through IgM will progress more rapidly than those that have low IgM signaling capacity or lower IgM levels.  
 
By targeting this molecule it may be possible to improve outcomes, says Forconi. A better understanding of how the BCR functions in CLL will make it easier to design a therapeutic regimen to fight the disease, he says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x